Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in weight management based on completed clinical studies and feedback received from regulatory authorities. 13 June 2025
Related News
Insights
Company Spotlight
A biotech company developing vectorized antibody approaches for the treatment of neurodegenerative diseases.
Latest News & Features of interest to Novo Nordisk
Pharmaceutical
USA-based Insmed Incorporated closed Tuesday’s trading up by more than a third. 11 June 2025
Biotechnology
South Korean biotech AriBio Co, specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi, announced an exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease. 11 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Pharmaceutical
Last month, the Future Health Report was presented at the World Health Assembly in Geneva, Switzerland. 10 June 2025
Pharmaceutical
UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO). 10 June 2025
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly 11% higher. 10 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 10 June 2025
Biotechnology
Dutch late-stage biotech NewAmsterdam Pharma late yesterday announced positive top-line data from prespecified Alzheimer’s disease (AD) biomarker analyses in the Phase III BROADWAY clinical trial (NCT05142722). The firm’s US-traded shares were up 4.1% at $20.99 in pre-market activity this morning. 10 June 2025
Biotechnology
Shares in US pharma giant Merck & Co were nearly 2% higher in early trading Monday. 9 June 2025
Latest In Brief for Novo Nordisk
Pharmaceutical
Shares of Swedish drugmaker Camurus shot up 23% to 638.50 kronor yesterday on news of that it has entered a collaboration and license agreement with Eli Lilly, granting the US pharma major exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology. 6 June 2025
Latest Related Ones To Watch News
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 10 June 2025
28 April 2025
17 April 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze